Jun 27 |
Can AbbVie Stock Keep Outpacing the S&P 500?
|
Jun 27 |
AbbVie gains FDA approval for EPKINLY in follicular lymphoma
|
Jun 26 |
U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma
|
Jun 26 |
AbbVie (ABBV) Parkinson's Candidate Faces 2nd FDA Rejection
|
Jun 26 |
Zealand hauls in $1B off obesity drug data; Curie.bio zeroes in on Series A’s
|
Jun 26 |
FDA issues complete response to AbbVie’s NDA for Parkinson’s drug
|
Jun 25 |
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
|
Jun 25 |
Cerevel Therapeutics sinks amid some worry on FTC review of AbbVie deal
|
Jun 25 |
AbbVie's Parkinson's Disease Therapy Hits FDA Roadblock
|
Jun 25 |
FDA snubs AbbVie Parkinson's combo
|